Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis.
- 1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Abstract
Background
Psoriasis is a prevalent immune-mediated inflammatory skin disease. Deucravacitinib, an oral selective allosteric tyrosine kinase 2 (TYK2) inhibitor, provides a novel therapeutic option, but real-world data on its short-term efficacy, safety, and predictors of response among Chinese patients remain limited.Objective
To evaluate the 12-week efficacy, safety, and predictors of response to deucravacitinib in Chinese patients with moderate-to-severe plaque psoriasis in a real-world setting.Methods
This prospective, single-center cohort study enrolled 120 adult patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index ≥10, body surface area ≥10%, or Dermatology Life Quality Index ≥10) at a tertiary hospital in Shanghai, China. All patients received oral deucravacitinib 6 mg once daily for 12 weeks.Results
Among the 120 patients (mean age, 37.2 years; 58.3% male), the week 12 PASI 75, PASI 90, and PASI 100 response rates were 59.6%, 24.0%, and 4.8%, respectively. Regional PASI 75 response rates were highest for the head and neck (79%), followed by the trunk (76%), lower limbs (74%), and upper limbs (72%). Baseline body mass index <24 kg/m² independently predicted higher PASI 90 achievement (odds ratio, 5.34; 95% CI, 1.28-22.21), but was not associated with PASI 75. Exploratory comparisons showed that PASI 75 non-responders had higher baseline levels of TNF-α, IL-1β, IL-23p19, IFN-γ, and G-CSF in exploratory comparisons, with no differences in other Th1, Th2, Th17, or regulatory T-cell cytokines. Adverse events occurred in 41 of 120 patients (34.2%); the most common events were acne (24/120, 20.0%), folliculitis (13/120, 10.8%), and upper respiratory tract infection (7/120, 5.8%), and most were mild to moderate.Conclusion
In this real-world study, deucravacitinib was associated with significant clinical improvement over 12 weeks and had a favorable safety profile in Chinese patients with moderate-to-severe psoriasis, including improvement in difficult-to-treat anatomical regions. Baseline body mass index <24 kg/m² and lower pretreatment levels of proinflammatory cytokines were associated with better treatment responses.
Related
- Efficacy and Safety of 5% Topical Caffeine Added to 0.025% Fluocinolone Acetonide Cream for Plaque Psoriasis: A Randomized Controlled Trial.
- Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials
- Clinical outcomes and predictors of poor prognosis among children with probable and confirmed bacterial meningitis in Northwest Ethiopia: a prospective multicenter cohort study
- Time to recovery and its predictors among pediatric patients with severe community-acquired pneumonia admitted to public general hospitals in Tigray, Ethiopia, 2025: A prospective follow-up study
- Predictors of quality of life in older adults with major psychiatric disorders: A prospective multicenter study
BibTeX
@article{dong2026prospective,
title = {{Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis.}},
author = {Canbin Dong and Yilun Wang and Jiazheng Sun and Jui-Ming Lin and Xiaonian Lu and Junhao Zhu and Lanmei Lin and Xinyi Zhu and Huiyu Huang and Jinhua Xu and Wenyu Wu and Juan Du},
journal = {Psoriasis (Auckland, N.Z.)},
year = {2026},
month = oct,
doi = {10.2147/ptt.s647993},
url = {https://europepmc.org/article/MED/42936288},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis.
AU - Canbin Dong
AU - Yilun Wang
AU - Jiazheng Sun
AU - Jui-Ming Lin
AU - Xiaonian Lu
AU - Junhao Zhu
AU - Lanmei Lin
AU - Xinyi Zhu
AU - Huiyu Huang
AU - Jinhua Xu
AU - Wenyu Wu
AU - Juan Du
PY - 2026
DA - 2026/10/22
JO - Psoriasis (Auckland, N.Z.)
DO - 10.2147/ptt.s647993
UR - https://europepmc.org/article/MED/42936288
AB - Background Psoriasis is a prevalent immune-mediated inflammatory skin disease. Deucravacitinib, an oral selective allosteric tyrosine kinase 2 (TYK2) inhibitor, provides a novel therapeutic option, but real-world data on its short-term efficacy, safety, and predictors of response among Chinese patients remain limited.Objective To evaluate the 12-week efficacy, safety, and predictors of response to deucravacitinib in Chinese patients with moderate-to-severe plaque psoriasis in a real-world setting.Methods This prospective, single-center cohort study enrolled 120 adult patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index ≥10, body surface area ≥10%, or Dermatology Life Quality Index ≥10) at a tertiary hospital in Shanghai, China. All patients received oral deucravacitinib 6 mg once daily for 12 weeks.Results Among the 120 patients (mean age, 37.2 years; 58.3% male), the week 12 PASI 75, PASI 90, and PASI 100 response rates were 59.6%, 24.0%, and 4.8%, respectively. Regional PASI 75 response rates were highest for the head and neck (79%), followed by the trunk (76%), lower limbs (74%), and upper limbs (72%). Baseline body mass index <24 kg/m² independently predicted higher PASI 90 achievement (odds ratio, 5.34; 95% CI, 1.28-22.21), but was not associated with PASI 75. Exploratory comparisons showed that PASI 75 non-responders had higher baseline levels of TNF-α, IL-1β, IL-23p19, IFN-γ, and G-CSF in exploratory comparisons, with no differences in other Th1, Th2, Th17, or regulatory T-cell cytokines. Adverse events occurred in 41 of 120 patients (34.2%); the most common events were acne (24/120, 20.0%), folliculitis (13/120, 10.8%), and upper respiratory tract infection (7/120, 5.8%), and most were mild to moderate.Conclusion In this real-world study, deucravacitinib was associated with significant clinical improvement over 12 weeks and had a favorable safety profile in Chinese patients with moderate-to-severe psoriasis, including improvement in difficult-to-treat anatomical regions. Baseline body mass index <24 kg/m² and lower pretreatment levels of proinflammatory cytokines were associated with better treatment responses.
SN - 2230-326X
ER -